Anemia: Symptoms, Causes, Diagnosis, and Treatment – A Complete Guide

What is Anemia?

Anemia is defined as an insufficient quantity of healthy red blood cells in the blood. From a clinical standpoint, the condition is diagnosed when the level of hemoglobin in the blood falls below the established normal threshold. Hemoglobin is the iron-rich protein found inside red blood cells that enables them to transport oxygen from the lungs to every organ and tissue in the body.

It is important to clarify a common misconception from the outset: “anemia” is not synonymous with “iron deficiency”. Anemia is defined by a deficiency of hemoglobin, not necessarily of iron. While iron deficiency is the most common cause of anemia worldwide, there are many other causes, ranging from vitamin deficiencies and inherited genetic conditions to chronic diseases, bone marrow disorders, and autoimmune processes.

If you suffer from anemia, your body does not have a sufficient supply of oxygenated blood. This is the fundamental cause of the characteristic symptoms, first and foremost fatigue, as well as the more serious consequences that can arise in untreated or severe cases:

• Fatigue and exhaustion: The most universal complaint, reflecting the tissues’ inadequate oxygen supply.
• Shortness of breath and breathlessness: Difficulty completing everyday activities, and in severe cases even at rest.

Anemia can be a temporary and easily correctable condition, or it can be a chronic, serious, and potentially life-threatening disorder. Many mild forms are readily treatable; others are complex, long-lasting, and require specialized, lifelong management. The clinical approach to anemia must therefore always begin with identifying the underlying cause, a step that is as important as treating the anemia itself.

Anemia affects an estimated 1.8 billion people worldwide, making it one of the most prevalent health conditions globally. It disproportionately affects women of reproductive age, children, the elderly, and individuals in low-income countries. In high-income countries, it is also a significant clinical burden, particularly in the context of chronic diseases, malignancy, surgery, and pregnancy.

---

Causes

Anemia can arise from a wide variety of underlying causes, but at a fundamental physiological level, all forms of anemia result from one or more of the following three mechanisms:

1. Excessive blood loss (acute hemorrhage or chronic bleeding) results in depletion of circulating red blood cells and their contained hemoglobin.
2. Insufficient production of red blood cells This can result from nutritional deficiencies, bone marrow disease, hormonal deficiencies (e.g., erythropoietin deficiency in renal failure), or inflammation that suppresses erythropoiesis.
3. Excessive destruction of red blood cells (hemolysis) This can be caused by inherited red blood cell defects, immune-mediated destruction, mechanical damage, or toxic injury.

In this comprehensive guide, we focus primarily on the most clinically prevalent forms, including anemia caused by:

• Deficiency of iron or other essential substrates (vitamins, folate)
• Aging and its associated physiological changes
• Surgical blood loss
• Chronic acquired conditions including:
  • Cancer (malignant tumors)
  • Diabetes mellitus
  • Chronic inflammatory bowel diseases (Crohn’s disease, ulcerative colitis)
  • Chronic kidney disease
  • Chronic heart disease
  • Hepatitis C
  • HIV/AIDS
  • Rheumatoid arthritis and other chronic inflammatory conditions

Anemia of Chronic Disease (ACD)

A particularly important and prevalent form in clinical practice is anemia of chronic disease (ACD), also called anemia of inflammation. It develops in the context of chronic infections, inflammatory conditions, autoimmune diseases, and malignancies. The underlying mechanism involves:

• Elevated hepcidin levels: In response to inflammation, the liver produces increased amounts of hepcidin, the master regulator of iron metabolism. Elevated hepcidin blocks iron absorption from the gut and traps iron inside macrophages and liver cells, making it unavailable for red blood cell production. This creates a state of “functional iron deficiency”: iron is present in the body but cannot be accessed for erythropoiesis.
• Suppression of erythropoiesis: Inflammatory cytokines (such as IL-6, TNF-α, and interferon-γ) directly suppress the bone marrow’s production of red blood cell precursors.
• Reduced erythropoietin response: The kidney’s production of erythropoietin (the hormone that stimulates red blood cell production) is blunted in inflammatory states.
• Shortened red blood cell lifespan: Inflammatory processes accelerate the destruction of circulating red blood cells.

Many patients with rheumatoid arthritis, chronic infections, or cancer develop ACD alongside or instead of iron deficiency anemia. This makes accurate diagnosis and targeted treatment particularly important.

Some Forms of Anemia Are Hereditary

Certain genetic mutations can reduce the production of red blood cells, cause structural or functional abnormalities in these cells, or impair their ability to carry oxygen efficiently. Inherited forms of anemia have been recognized for centuries, and molecular genetic research has dramatically expanded our understanding of the genetic bases of these conditions.

Inherited red blood cell abnormalities may result in:

• Shortened red blood cell lifespan: cells are fragile and destroyed prematurely.
• Reduced oxygen-carrying efficiency: hemoglobin is structurally abnormal and cannot bind or release oxygen normally.
• Insufficient red blood cell production: the bone marrow cannot produce adequate numbers of functional red blood cells.

Well-recognized hereditary anemias include:

• Sickle cell anemia: A hemoglobin structural defect causing red blood cells to assume a rigid sickle shape, leading to chronic hemolysis and vaso-occlusive crises.
• Thalassemia (Mediterranean anemia): Reduced or absent production of one of the hemoglobin chain types, causing ineffective erythropoiesis and chronic anemia of variable severity.
• Diamond-Blackfan anemia: A rare congenital bone marrow failure syndrome characterized by isolated red blood cell aplasia, often associated with physical malformations.
• Fanconi anemia: A complex inherited disorder affecting DNA repair, causing bone marrow failure, congenital malformations, and elevated cancer risk.

Additional hereditary conditions that can secondarily cause or contribute to anemia include:

• Shwachman-Diamond syndrome.
• Red blood cell membrane abnormalities (hereditary spherocytosis, hereditary elliptocytosis).
• G6PD deficiency (favism) is the most common enzymopathy in the world. It causes hemolytic anemia triggered by oxidative stress from certain foods, drugs, or infections.
• Hereditary hemorrhagic telangiectasia (HHT).
• Dyskeratosis congenita.
• Congenital dyserythropoietic anemias (CDA).
• Congenital syndromes of vitamin B12 malabsorption (e.g., Imerslund-Gräsbeck syndrome).

Risk Factors

Several identifiable factors significantly increase an individual’s risk of developing anemia:

• Neonates and infants: Babies who do not receive sufficient iron in their diet (particularly premature infants, whose iron stores are limited) are at risk of iron deficiency anemia during rapid early growth.
• Children during growth spurts: During periods of rapid physical growth, iron demand for expanding red blood cell production may outpace dietary iron intake, creating a period of relative iron deficiency.
• Women of reproductive age: Menstruation results in regular blood (and iron) loss. Women with heavy menstrual bleeding are particularly vulnerable, as the monthly iron loss can exceed dietary intake, gradually depleting iron stores.
• Pregnant women: The developing fetus requires substantial iron for its own growth and red blood cell production. This iron is largely derived from the mother’s reserves, significantly increasing her iron requirements during pregnancy (see Anemia in Women section).
• Patients with chronic kidney disease (CKD): The kidneys are the primary site of erythropoietin production. Renal insufficiency reduces erythropoietin levels, impairing the bone marrow’s ability to produce red blood cells. Additionally, CKD patients are often iron deficient due to reduced dietary intake, increased losses through dialysis, and impaired absorption.
• Patients with gastrointestinal bleeding: Chronic, often occult (hidden), blood loss from the gastrointestinal tract due to peptic ulcers, colorectal polyps, colorectal cancer, angiodysplasia, or other lesions is a major cause of iron deficiency anemia, particularly in middle-aged and older adults.
• Cancer patients receiving radiotherapy or chemotherapy: Chemotherapy-related anemia is extremely common. Cytotoxic drugs damage the bone marrow’s capacity to produce not only red blood cells but also white blood cells and platelets, causing pancytopenia. Radiotherapy directed at bones containing active bone marrow can have similar effects.
• Patients with leukemia and other hematological malignancies: Disease processes in the bone marrow directly displace or suppress normal blood cell production.
• Patients with chronic inflammatory diseases: Including rheumatoid arthritis and chronic infections, which cause ACD through the mechanisms described above.
• The elderly: The prevalence of anemia increases significantly with advancing age. The most common contributors include chronic inflammation (which suppresses bone marrow activity), reduced erythropoietin production, nutritional deficiencies (particularly of iron, B12, and folate), and the accumulation of chronic diseases. Importantly, anemia in older adults is associated with significantly worse outcomes, including increased frailty, falls, cognitive decline, hospitalization, and mortality, making its diagnosis and treatment clinically impactful for quality of life.

Medications Can Cause Anemia

A wide range of commonly used medications can cause or contribute to anemia through various mechanisms:

Chemotherapy agents: These are perhaps the most widely recognized drug-related cause of anemia. Cytotoxic drugs (such as platinum compounds, taxanes, and anthracyclines) damage the bone marrow’s blood-forming cells, reducing production of red blood cells and often all blood cell types during and after treatment.

Drug-induced aplastic anemia: Certain medications can trigger aplastic anemia, a severe and potentially life-threatening failure of bone marrow production, through idiosyncratic (unpredictable, immune-mediated) reactions. The mechanisms are not fully understood, and not all patients exposed to the same drug are equally at risk. Some individuals appear to have inherited susceptibilities. Examples include certain antibiotics (chloramphenicol), NSAIDs, and antiepileptics.

G6PD-triggering agents: In individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency (the most common hereditary enzymopathy, affecting an estimated 400 million people worldwide), exposure to specific drugs (such as primaquine, dapsone, nitrofurantoin, and certain sulfonamides) or foods (notably fava beans, which give the condition its alternative name “favism”) triggers acute hemolytic anemia. G6PD is a critical enzyme that protects red blood cells from oxidative stress; without it, red blood cells are vulnerable to oxidative damage and rupture.

Antiretroviral agents: Zidovudine (AZT), used in HIV treatment, can suppress bone marrow production and cause macrocytic anemia.

Proton pump inhibitors and metformin: Long-term use of these widely prescribed medications can impair vitamin B12 absorption (PPIs by reducing gastric acid; metformin by interfering with ileal B12 absorption), potentially leading to megaloblastic anemia over time if B12 status is not monitored.

NSAIDs and aspirin: These drugs increase the risk of gastrointestinal bleeding (from peptic ulcers, erosions, and gastric irritation), which can cause iron deficiency anemia through chronic blood loss.

---

Symptoms

Anemia produces a wide spectrum of symptoms, ranging from none at all (in mild or slowly developing cases) to severe, debilitating, and life-threatening manifestations (in advanced or rapidly developing cases). The specific symptoms depend on:

• The degree of anemia (how low the hemoglobin is)
• The speed of onset (acute vs. chronic)
• The patient’s age and cardiovascular reserve
• The underlying cause

The most commonly reported symptoms of anemia include:

General and constitutional symptoms:

• Fatigue and exhaustion: The most universal and often the earliest symptom of anemia. The fatigue of anemia is characteristically disproportionate to the level of activity. Patients feel tired with minimal exertion and may struggle to complete previously easy tasks.
• Weakness: Generalized physical weakness and reduced muscle strength, reflecting inadequate oxygen delivery to skeletal muscles.
• Dizziness and lightheadedness: Particularly on standing (orthostatic symptoms), due to reduced cerebral oxygen perfusion.
• Irritability: Mood changes, emotional lability, and increased irritability are often subtle early symptoms that patients and caregivers may not immediately associate with anemia.
• Shortness of breath (dyspnea): Initially occurring only on exertion (climbing stairs, walking briskly), and progressing to dyspnea at rest in severe anemia.
• Depression: Chronic fatigue, reduced vitality, and impaired cognitive function associated with anemia can contribute to depressive symptoms.

Cardiovascular and respiratory symptoms:

• Palpitations: An uncomfortable awareness of the heart beating rapidly or forcefully, as the heart increases its output to compensate for reduced oxygen-carrying capacity.
• Chest pain or discomfort: In patients with pre-existing coronary artery disease, significant anemia can precipitate angina by reducing the oxygen supply to the heart muscle.
• Cardiac arrhythmias: In severe or prolonged anemia, the cardiac strain can disrupt normal heart rhythm.

Physical signs:

• Pale skin: The reduction in hemoglobin, which gives blood its red color, produces characteristic pallor of the skin, mucous membranes (inner lips, gums), nail beds, and conjunctivae (the inner lining of the eyelids). Examining the conjunctivae is particularly useful clinically.
• Brittle, breaking nails: Particularly associated with iron deficiency anemia; nails may become thin, brittle, and concave (koilonychia, known as “spoon nails”).
• Cold extremities: Peripheral vasoconstriction as blood is redirected to vital organs can cause cold hands and feet.

Other symptoms:

• Difficulty concentrating: Impaired mental clarity, poor short-term memory, and reduced cognitive performance, reflecting inadequate oxygen delivery to the brain.
• Sexual dysfunction: Chronic severe anemia can impair libido and sexual function.
• Pica: The unusual craving for non-food substances (see dedicated section below).

Anemia Can Be Asymptomatic

Patients with mild anemia may experience no symptoms whatsoever, or symptoms so subtle that they are dismissed or attributed to other causes (stress, poor sleep, aging). In many cases, anemia is diagnosed incidentally, detected on routine blood tests ordered for other reasons.

The ability to tolerate anemia without symptoms depends critically on the speed of onset:

• Gradually developing anemia (over months or years, as often occurs with nutritional deficiency or chronic disease) allows the body to adapt through multiple compensatory mechanisms: increased cardiac output, redistribution of blood flow to vital organs, increased production of 2,3-diphosphoglycerate (2,3-DPG) in red blood cells (which enhances oxygen release to tissues), and preferential perfusion of oxygen-sensitive organs (brain and heart). These adaptations can maintain relatively normal function despite substantially reduced hemoglobin levels, explaining why some patients remain asymptomatic until anemia is quite severe.
• Rapidly developing anemia (e.g., acute hemorrhage) produces symptoms quickly because compensatory mechanisms have not had time to develop.

An important and often underappreciated consequence of untreated, worsening anemia is its effect on the heart. As anemia deepens, the heart works progressively harder to maintain adequate oxygen delivery. Initially, the increased pumping activity can slow symptom onset. However, chronically sustained cardiac overload causes the left ventricular muscle to thicken, a condition called left ventricular hypertrophy (LVH), which can eventually lead to heart failure. This progression underscores the importance of treating even “mild” chronic anemia rather than dismissing it as unimportant.

Craving Ice Is a Symptom of Anemia

An unusual but clinically well-recognized symptom of iron deficiency anemia (and, less commonly, other deficiencies) is pica, the persistent craving and consumption of non-nutritive, often inedible substances.

Pagophagia, the craving specifically for ice, is the most common and distinctive form of pica associated with iron deficiency. Other manifestations of pica in iron deficiency include cravings for:

• Starch (amylophagia)
• Uncooked rice or flour
• Paper
• Chalk or clay (geophagia)
• Dirt or soil

The precise mechanism linking iron deficiency to pica is not fully understood. One proposed explanation involves iron’s role as a cofactor for enzymes involved in central nervous system neurotransmitter metabolism: iron deficiency may alter dopamine signaling in brain regions that regulate reward and craving behavior, potentially driving the compulsive urge to consume unusual substances. Another hypothesis suggests that chewing ice may briefly relieve the inflammation and soreness of the mouth associated with iron deficiency–related glossitis.

Patients are usually unable to voluntarily control these cravings, and they typically resolve promptly with iron replacement therapy.

Clinical importance: If you notice yourself or someone else craving ice, chalk, paper, or any other non-food substance, this symptom should be taken seriously and reported to a physician, as it may be an early indicator of iron deficiency anemia.

---

Diagnosis

The diagnosis of anemia requires a structured clinical evaluation. Modern diagnostic practice aims not only to confirm the reduction in hemoglobin but also, equally importantly, to identify the underlying cause in order to target treatment appropriately. Treating anemia without identifying its cause is inadequate medicine: it is akin to treating a fever without looking for the infection.

First-Line Blood Tests

The cornerstone of anemia diagnosis is the complete blood count (CBC). This routine blood test quantifies all major blood cell types and provides key morphological parameters. The clinician evaluates:

• Hemoglobin (Hb): The primary diagnostic criterion for anemia. By widely used criteria (WHO and most national guidelines), anemia is defined as:

  • Hb < 13.0 g/dL in adult men
  • Hb < 12.0 g/dL in non-pregnant adult women
  • Hb < 11.0 g/dL in pregnant women
  • Different thresholds apply in children, varying by age

• Mean corpuscular volume (MCV): The average volume of individual red blood cells. MCV is the most powerful initial classifier of anemia:

  • Microcytic anemia (low MCV, <80 fL): Suggests iron deficiency, thalassemia, or anemia of chronic disease
  • Normocytic anemia (normal MCV, 80–100 fL): Suggests acute blood loss, hemolysis, early nutritional deficiency, anemia of chronic disease, or bone marrow failure
  • Macrocytic anemia (high MCV, >100 fL): Suggests vitamin B12 or folate deficiency, liver disease, hypothyroidism, or medication effects

• Red cell distribution width (RDW): Quantifies the variability in red blood cell size (anisocytosis). An elevated RDW suggests a nutritional deficiency or a mixed anemia (e.g., simultaneous iron and B12 deficiency), while a normal RDW in the context of microcytosis is more typical of thalassemia trait.

• Reticulocyte count: Reticulocytes are the young, newly released red blood cells; their count reflects the bone marrow’s current rate of red blood cell production.

  • Low reticulocyte count in the context of anemia indicates hypoproductive (hypoproliferative) anemia, meaning the bone marrow is failing to respond adequately. This can occur due to conditions such as iron deficiency, nutritional deficiency, aplastic anemia, or bone marrow infiltration.
  • Elevated reticulocyte count in the context of anemia indicates a hyperproductive (hyperregenerative) response: the bone marrow is working overtime to replace red blood cells that are being lost or destroyed (for example, acute hemorrhage or hemolytic anemia).

• White blood cell and platelet counts: Reductions in white blood cells (leukopenia) and/or platelets (thrombocytopenia) alongside anemia (pancytopenia) suggest bone marrow failure, infiltration by malignancy, or severe nutritional deficiency affecting all cell lineages.

Iron Metabolism Studies and Biomarkers

When the CBC suggests iron deficiency (typically microcytic, hypochromic anemia with elevated RDW), the next step is a comprehensive iron panel to evaluate the body’s iron status:

• Serum ferritin: The most reliable single indicator of total body iron stores. Low ferritin is an unequivocal marker of iron deficiency. However, ferritin is also an acute-phase reactant, meaning it rises with inflammation, infection, and liver disease, even when true iron stores are depleted. This means that in patients with concurrent inflammation, ferritin may appear “normal” despite actual iron deficiency, a diagnostic pitfall that can lead to undertreatment.

• Transferrin saturation (TSAT): The percentage of transferrin (the main iron-transport protein) that is saturated with iron, reflecting the immediate availability of iron for red blood cell production. TSAT below 20% (or 16% by some criteria) indicates iron deficiency or restricted iron delivery to the bone marrow.

• Serum iron (sideremia) and transferrin: Iron is the amount of iron directly circulating in the blood; transferrin is the carrier protein. Together with TSAT, they provide a complete picture of iron transport dynamics.

• Soluble transferrin receptor (sTfR): An advanced biomarker that is not affected by inflammation, which makes it particularly useful in the challenging clinical scenario of distinguishing pure iron deficiency anemia from anemia of chronic disease (where ferritin is elevated and cannot be used as a reliable marker). Elevated sTfR indicates tissue iron deficiency regardless of concurrent inflammation. The sTfR/log ferritin ratio (the “ferritin index”) further improves diagnostic accuracy.

• Hepcidin levels: Increasingly used in clinical research and specialized centers, hepcidin measurement helps elucidate the mechanism of iron restriction in complex cases (high hepcidin in ACD, low hepcidin in iron deficiency).

Advanced Diagnostic Investigations and Imaging

Once anemia is confirmed and its general type established, identifying the specific underlying cause is essential, particularly if blood loss is suspected:

• Fecal immunochemical test (FIT) for occult blood: A non-invasive stool test that detects microscopic blood loss from the gastrointestinal tract. It is a critical investigation in any patient with iron deficiency anemia, particularly middle-aged and older adults, to exclude colorectal cancer and other GI sources of bleeding.

• Endoscopic investigations:

  • Gastroscopy (upper GI endoscopy): To evaluate for peptic ulcers, erosive gastritis, esophageal varices, celiac disease (duodenal biopsy), or upper GI malignancy as sources of occult blood loss or malabsorption.
  • Colonoscopy: To evaluate for colorectal polyps, colorectal cancer, angiodysplasia, or inflammatory bowel disease.

• Serum vitamin B12 and folate levels: To identify megaloblastic causes of macrocytic anemia. If B12 is borderline, measurement of serum methylmalonic acid (MMA) and homocysteine, which are metabolically sensitive functional markers of B12 adequacy, can confirm deficiency.

• Renal function tests (creatinine, eGFR) and erythropoietin level: To evaluate the possibility of anemia of chronic kidney disease and assess erythropoietin production.

• Thyroid function tests (TSH): Hypothyroidism can cause macrocytic anemia and should be excluded, particularly in women and older adults.

• Liver function tests: Liver disease is an important cause of macrocytosis and can impair erythropoiesis.

• Peripheral blood smear: Microscopic examination by an experienced hematologist can provide invaluable morphological clues, including sickle cells, target cells, teardrop cells, spherocytes, schistocytes (fragmented cells), hypersegmented neutrophils, and many other specific findings, that point toward particular diagnoses.

• Bone marrow biopsy and aspiration: Reserved for complex cases where the diagnosis remains uncertain after non-invasive workup, where a primary bone marrow disorder (aplastic anemia, MDS, leukemia, myeloma) is suspected, or where the anemia does not respond to expected treatment.

• Hemoglobin electrophoresis / HPLC: When hereditary hemoglobinopathy (thalassemia, sickle cell disease) is suspected, these tests identify and quantify the specific hemoglobin variants present.

• Direct Coombs test (direct antiglobulin test, DAT): When autoimmune hemolytic anemia is suspected, this test detects antibodies or complement proteins bound to the surface of the patient’s red blood cells.

• Genetic testing: For confirmed or suspected hereditary anemias, targeted or panel-based genetic testing can identify specific causative mutations.

---

Treatment and Therapy

The primary goal of treatment is to restore physiological hemoglobin levels and, simultaneously, to resolve or manage the underlying condition responsible for the anemia. The modern approach is increasingly personalized, based on the specific type and cause of anemia, its severity, the patient’s symptoms and clinical stability, and individual factors such as tolerance to specific therapies.

Treating anemia without addressing the underlying cause will inevitably result in relapse. For example, treating iron deficiency anemia with iron supplements is effective, but if the underlying cause (such as gastrointestinal bleeding from a colorectal cancer) is not identified and treated, the anemia will recur.

Iron and Nutrient Supplementation

For the most common form, iron deficiency anemia (sideropaenic anemia), iron replacement therapy is the cornerstone of treatment.

Oral Iron Supplementation

Oral iron is the first-line treatment for iron deficiency in most patients without malabsorption. Available preparations include:

• Ferrous sulfate, ferrous gluconate, ferrous fumarate: Traditional ferrous (Fe²⁺) iron salts are generally highly effective and inexpensive. However, they are frequently associated with gastrointestinal side effects, particularly nausea, abdominal cramps, constipation, and dark stools.
• Optimal dosing strategy: Current evidence suggests that alternate-day dosing (e.g., taking iron every other day rather than daily) significantly improves intestinal iron absorption and reduces side effects. The reasoning is that each oral iron dose transiently raises hepcidin levels for 24–48 hours, which reduces iron absorption from the next consecutive dose. Allowing 24 hours between doses avoids this hepcidin-mediated inhibition.
• Innovative formulations: Newer formulations, including liposomal iron and sucrosomial iron, encapsulate iron in a protective lipid or phospholipid matrix. This allows it to pass through the gastrointestinal mucosa without causing local irritation, dramatically reducing side effects while maintaining excellent absorption. These preparations are particularly suitable for patients who are intolerant of conventional iron salts.

Intravenous Iron

Intravenous (IV) iron bypasses the gastrointestinal tract entirely and delivers iron directly into the bloodstream, where it is immediately available for red blood cell production. It is indicated when:

• The patient cannot tolerate oral iron due to significant gastrointestinal side effects
• There is documented malabsorption (e.g., celiac disease, inflammatory bowel disease, bariatric surgery)
• Rapid iron repletion is required (e.g., before elective surgery to correct preoperative anemia)
• Chronic iron losses exceed what can be replaced orally (e.g., ongoing gastrointestinal bleeding)
• Oral iron is simply ineffective (e.g., in patients receiving dialysis or those with high hepcidin levels)

Modern IV iron preparations (ferric carboxymaltose, ferric derisomaltose, low-molecular-weight iron dextran) are highly safe and allow administration of large doses (up to the entire calculated iron deficit) in a single infusion session lasting 15–60 minutes, dramatically improving treatment efficiency compared to older preparations that required multiple slow infusions.

Vitamin B12 and Folic Acid

For megaloblastic anemia caused by vitamin B12 or folate deficiency:

• Vitamin B12 can be administered orally (high-dose, 1000–2000 mcg daily, when the cause is dietary deficiency) or by intramuscular injection (when malabsorption, such as in pernicious anemia, prevents oral absorption). Intramuscular B12 is typically required for life in patients with pernicious anemia or permanent malabsorption.
• Folic acid is administered orally (typically 5 mg/day) for folate deficiency. It is crucial that B12 deficiency is always excluded or simultaneously treated when prescribing folate, as treating folate deficiency alone in a B12-deficient patient can mask the anemia while neurological damage from B12 deficiency progresses unchecked.
• Periconceptional folic acid supplementation (400–800 mcg/day, starting at least 1 month before conception and continuing through the first trimester) is recommended for all women planning pregnancy to prevent fetal neural tube defects.

Advanced Pharmacological Therapies

For anemias arising from chronic disease, renal failure, or bone marrow disorders, more targeted pharmacological interventions are available:

Erythropoiesis-Stimulating Agents (ESAs)

ESAs are synthetic versions or analogs of erythropoietin, the endogenous hormone produced primarily by the kidneys that drives the bone marrow to produce red blood cells. Examples include epoetin alfa, epoetin beta, and darbepoetin alfa.

ESAs are the standard pharmacological treatment for:

• Anemia of chronic kidney disease (CKD): Particularly in patients on dialysis or pre-dialysis patients with symptomatic anemia.
• Chemotherapy-induced anemia: In patients with non-myeloid malignancies receiving myelosuppressive chemotherapy with non-curative intent, where ESAs can reduce transfusion requirements and improve quality of life.

ESA therapy is always used in conjunction with adequate iron supplementation, as iron is the essential building block for the hemoglobin produced by the stimulated bone marrow. Functional iron deficiency is common during ESA therapy and must be corrected, often with IV iron, to ensure an adequate treatment response.

HIF-Prolyl Hydroxylase Inhibitors (HIF-PHIs)

A novel and clinically important class of oral agents that stabilize hypoxia-inducible factor (HIF), a transcription factor that, under normal physiological hypoxic conditions, stimulates erythropoietin production and enhances iron availability for erythropoiesis. By inhibiting the enzymes (prolyl hydroxylases) that normally mark HIF for degradation, HIF-PHIs (such as roxadustat, daprodustat, and vadadustat) produce a sustained “hypoxia-mimicking” effect that:

• Stimulates endogenous erythropoietin production
• Suppresses hepcidin (thereby improving iron availability for erythropoiesis)
• Increases transferrin production

HIF-PHIs are approved in several countries for the treatment of anemia of chronic kidney disease, offering the significant advantage of oral administration compared to injectable ESAs. Clinical evidence suggests efficacy comparable to ESAs, with particular advantages in managing the iron regulation component of CKD-related anemia.

Luspatercept

An erythroid maturation agent that promotes the differentiation of late-stage erythroid precursors. Approved for treatment of:

• Transfusion-dependent beta-thalassemia
• Myelodysplastic syndrome with ring sideroblasts (MDS-RS)

Luspatercept is administered subcutaneously every 3 weeks and has demonstrated significant reduction in transfusion burden in clinical trials.

Transfusions and Emergency Interventions

Red blood cell transfusion is the most immediately effective intervention for severe anemia but is now used according to restrictive, evidence-based criteria in most clinical settings:

• Most guidelines recommend transfusion when hemoglobin falls below 7–8 g/dL in hemodynamically stable patients without cardiac disease, or at higher hemoglobin thresholds (8–10 g/dL) in patients with active cardiac ischemia, hemodynamic instability, or severe symptoms attributable to anemia.
• Liberal transfusion strategies (transfusing at higher hemoglobin thresholds) have not been shown to improve outcomes compared to restrictive strategies in most patient populations and are associated with increased risks (including transfusion reactions, alloimmunization, iron overload, volume overload, and transfusion-transmitted infections).
• Transfusion thresholds should always be individualized based on the patient’s symptoms, cardiorespiratory reserve, and clinical context.

Lifestyle and Diet

Dietary and lifestyle measures are fundamental for preventing relapse and supporting pharmacological therapy:

Dietary iron optimization:

• Foods richest in heme iron (the most bioavailable form, found only in animal products) include lean red meat, poultry, fish, and shellfish. Heme iron is absorbed at rates of 15–35%, far exceeding the 2–20% absorption of non-heme iron from plant sources.
• Rich sources of non-heme iron (found in both animal and plant foods) include legumes (lentils, chickpeas, kidney beans), dark green leafy vegetables (spinach, kale), tofu, fortified cereals, and whole grains.
• Maximize iron absorption:
  • Consume vitamin C-rich foods (e.g., citrus fruits, bell peppers, tomatoes, kiwi) simultaneously with iron-containing meals. Vitamin C dramatically enhances non-heme iron absorption by reducing ferric iron (Fe³⁺) to the more absorbable ferrous form (Fe²⁺).
  • Choose a Mediterranean-style diet (diverse, plant-rich, and including regular moderate portions of lean meat and fish) as the overall dietary pattern with the strongest evidence for supporting iron status and overall health.
• Reduce iron absorption inhibitors at mealtimes:
  • Avoid consuming large amounts of tea or coffee with iron-rich meals, as the tannins in these beverages significantly inhibit non-heme iron absorption. These beverages are best consumed between meals.
  • Calcium-rich foods and supplements (dairy products, calcium supplements) also inhibit iron absorption when consumed simultaneously.

Hydration and physical activity:

• Adequate hydration supports cardiovascular function and helps alleviate the fatigue associated with anemia.
• Moderate, regular physical activity, such as walking, gentle cycling, or swimming, is beneficial during recovery. It improves cardiovascular efficiency and combats the sense of exhaustion. Patients should consult their physician regarding safe activity levels, particularly in severe anemia.

---

Anemia in Women

Women face a disproportionately higher risk of developing anemia than men throughout much of their lives, primarily because of the physiological iron losses associated with menstruation and the dramatically increased iron demands of pregnancy.

Menstrual Cycle

Heavy menstrual bleeding (menorrhagia), defined as menstrual blood loss exceeding 80 mL per cycle, is one of the most common causes of iron deficiency anemia in women of reproductive age. Studies estimate that menorrhagia affects 10–15% of women at least once in their lifetime, and of these, approximately 20% will develop iron deficiency anemia.

The iron lost with each menstrual cycle varies substantially between women. Women with heavy periods can lose considerably more iron per month than can be replaced through the diet alone, leading to a progressive depletion of iron stores over time.

Management strategies include:

• Dietary optimization: Increasing iron-rich food intake (lean red meat, legumes, dark leafy vegetables) and using dietary strategies to maximize absorption (vitamin C with meals, tea between meals).
• Oral iron supplementation: When dietary measures are insufficient, oral iron supplements are used to replete iron stores. The dose and duration of supplementation should be guided by laboratory monitoring of ferritin and hemoglobin.
• Gynecological evaluation: Women with significant menorrhagia should be evaluated by a gynecologist to identify and treat the underlying cause (e.g., uterine fibroids, adenomyosis, hormonal imbalance, coagulation disorders). Treating the cause of heavy bleeding is the most effective long-term strategy for preventing recurrent iron deficiency anemia.
• Hormonal treatment: Various hormonal therapies (combined oral contraceptives, the levonorgestrel-releasing intrauterine system, progestins, and others) can significantly reduce menstrual blood loss in eligible women.

Uterine Fibroids and Anemia

Anemia in women can be caused by heavy menstrual bleeding associated with uterine fibroids. These are benign (non-cancerous) smooth muscle tumors of the uterus that are extremely common among women of reproductive age. Fibroids are estimated to affect up to 70–80% of women by age 50, though many are asymptomatic.

Importantly, uterine fibroids virtually never undergo malignant transformation and do not represent a risk factor for uterine cancer. However, when they cause heavy, prolonged menstrual bleeding, the resulting iron losses can produce significant anemia.

Management of fibroid-related anemia involves addressing both components:

• Iron replacement therapy to correct anemia (oral or IV iron, depending on severity and the urgency of treatment)
• Treatment of the fibroids themselves: Options range from hormonal therapies (to reduce fibroid size and control bleeding before definitive treatment) to minimally invasive procedures (uterine fibroid embolization, focused ultrasound surgery) and surgical options (myomectomy, hysterectomy), depending on patient preferences, reproductive goals, and clinical circumstances.

Anemia and Pregnancy

Pregnancy dramatically increases the body’s demand for iron. The pregnant woman must supply adequate iron not only to maintain her own increased blood volume (which expands by approximately 40–50% during pregnancy) but also to support the developing fetus, which is building its own blood supply and iron stores.

Key facts about anemia in pregnancy:

• Iron requirements nearly double during pregnancy: While non-pregnant women need approximately 18 mg of iron per day, pregnant women require an estimated 27 mg per day, a 50% increase. A healthy, varied diet typically provides only 12–14 mg of iron per day, making supplementation essential for most pregnant women.

• Folate requirements also increase: Adequate folate is essential for fetal neural tube development. The recommended daily folate intake increases from 400 mcg to 600 mcg during pregnancy (and ideally 400–800 mcg/day from periconception). All pregnant women are advised to take folic acid supplements.

• Anemia in pregnancy is common: Iron deficiency is the most prevalent nutritional deficiency in pregnancy worldwide. The WHO estimates that anemia affects approximately 38% of pregnant women globally.

• Hemoglobin thresholds in pregnancy differ from the non-pregnant state: Due to the physiological hemodilution of pregnancy (blood volume expands more than red blood cell mass), hemoglobin levels naturally decline in the second trimester. Most guidelines define anemia in pregnancy as:

  • Hb < 11.0 g/dL in the first and third trimesters
  • Hb < 10.5 g/dL in the second trimester
  • Hb < 8.5 g/dL is associated with significantly increased risk of adverse neonatal outcomes

• CDC recommendations: The CDC (Centers for Disease Control and Prevention) recommends that all pregnant women take 30 mg of elemental iron daily as a supplement, in addition to consuming a diet rich in iron and folate-containing foods (including lean meat, fish, dark leafy green vegetables, and liver).

• Consequences of anemia in pregnancy: Untreated significant anemia in pregnancy is associated with increased risk of preterm birth, low birthweight, maternal fatigue, impaired immune function, and, in severe cases, maternal cardiac decompensation.

Childbirth and Postpartum Anemia

Approximately 10% of women develop anemia within the first six months after delivery, and an estimated 4% remain anemic for up to 12 months postpartum.

Anemia that develops in the period following childbirth is called postpartum anemia and is most commonly caused by iron deficiency. Contributing factors include:

• Significant blood loss at delivery: Vaginal deliveries involve an average blood loss of approximately 300–500 mL; cesarean sections typically involve 700–1000 mL. Excessive bleeding (postpartum hemorrhage, defined as blood loss >500 mL after vaginal delivery or >1000 mL after cesarean) significantly worsens iron depletion.
• Multiple pregnancy (twins or more): Greater blood volume demands during pregnancy and greater potential blood loss at delivery increase the risk.
• Pre-existing anemia in the third trimester: Women who enter delivery already anemic have less physiological reserve to tolerate blood loss.

After delivery, the mother’s body must rapidly rebuild red blood cell production to compensate for the lost blood. This requires adequate iron to synthesize the necessary hemoglobin. Without sufficient iron stores, the bone marrow cannot mount this response, and the anemia persists.

Postpartum anemia can have significant consequences for new mothers, including:

• Profound fatigue and reduced physical capacity directly impair the ability to care for the newborn
• Impaired cognitive function and emotional resilience
• Contribution to postpartum depression
• Reduced breast milk production (in severe cases)

Management includes iron supplementation (oral or IV, depending on severity), dietary optimization, and, in severe symptomatic anemia, transfusion. Women with significant postpartum anemia or risk factors for it should remain in close contact with their obstetrician and primary care physician.

---

Myths to Debunk

Does Anemia Cause Hair Loss?

Anemia itself does not cause hair loss, neither temporarily nor permanently.

However, some patients who are anemic also experience hair loss, which creates a perceived association. This overlap occurs because the underlying factors that cause anemia can also independently cause hair loss:

• Nutritional deficiencies, including iron deficiency (which is associated with hair thinning but distinct from the direct cause of anemia), vitamin B12 deficiency, and zinc deficiency
• Hyperthyroidism or hypothyroidism: thyroid disorders can cause both anemia and hair loss.
• Chemotherapy cycles: chemotherapy causes both bone marrow suppression (leading to anemia) and hair loss
• Autoimmune conditions: conditions like lupus or alopecia areata can affect both hematopoiesis and hair follicles

Other common causes of hair loss unrelated to anemia include:

• Genetic predisposition (androgenetic alopecia)
• Diabetes mellitus
• Skin conditions (lupus erythematosus, lichen planus)
• Thyroid disorders
• Hormonal fluctuations (postpartum, menopause, hormonal contraceptives)
• Physical or emotional stress
• Excessive heat styling or traction hairstyles
• Poor nutrition or extreme caloric restriction
• Radiotherapy

If you are experiencing simultaneous hair loss and symptoms suggestive of anemia, report both to your physician. The combination of symptoms may help identify a shared underlying cause and guide appropriate treatment.

Does Lack of Sleep Cause Anemia?

Sleep deprivation and insomnia do not directly cause anemia. However, many patients believe the two are connected because they share overlapping symptoms:

Symptoms common to both conditions:

• Fatigue and exhaustion
• Weakness and reduced physical capacity
• Irritability
• Difficulty concentrating and impaired cognitive performance

The confusion is understandable, but the mechanism is different. In anemia, symptoms arise from reduced oxygen delivery to tissues. In sleep deprivation, symptoms arise from insufficient cellular restoration during sleep and dysregulation of neurological and hormonal systems.

That said, there is an indirect relationship worth acknowledging: the underlying cause of sleep disruption, whether it is a chronic illness, pain, respiratory disorder, or other condition, may independently contribute to the development of anemia. For example, chronic inflammatory conditions cause both disturbed sleep and anemia of chronic disease.

Does Blood Donation Affect Circulating Iron Levels?

Yes, blood donation does affect iron levels. Each blood donation removes approximately 250 mg of iron from the body, contained in the hemoglobin of the donated red blood cells.

This iron loss is reflected in a measurable decrease in serum ferritin (the marker of iron stores) in the days to weeks following donation. However, serum iron (sideremia) remains relatively stable in the short term, as the body compensates by increasing iron release from storage.

Iron stores typically return to pre-donation levels within 6 to 12 weeks in individuals with adequate dietary iron intake, as the bone marrow and reticuloendothelial system recycle iron from the breakdown of older red blood cells and dietary absorption is transiently upregulated.

Important implications for regular blood donors:

• Regular donors, particularly women and individuals with lower iron stores at baseline, may develop iron deficiency over time if the rate of iron loss through donation exceeds dietary replacement.
• Blood donation centers routinely screen donors for hemoglobin levels before each donation to exclude those who are already anemic.
• Regular donors may benefit from periodic monitoring of ferritin levels and, if deficiency develops, dietary counseling and/or iron supplementation in the intervals between donations.

---

Frequently Asked Questions

What should I eat if I have anemia?

The honest answer is: it depends on the type of anemia. Different types of anemia require different dietary strategies, and in some cases, opposite approaches.

• Iron deficiency anemia: Consume iron-rich foods (lean red meat, fish, shellfish, legumes, lentils, dark leafy greens, whole grains), always paired with a source of vitamin C (orange juice, bell peppers, tomatoes) to maximize iron absorption. Avoid drinking tea or coffee with iron-rich meals.
• Mediterranean anemia (thalassemia): Iron-rich foods should be limited or avoided, particularly in patients with iron overload. Dietary strategy must be individualized with a specialist’s guidance.
• Megaloblastic anemia from B12 or folate deficiency: Focus on foods rich in vitamin B12 (meat, fish, eggs, dairy) and folate (dark leafy greens, legumes, fortified cereals) and consider supplementation. A vegan diet requires mandatory B12 supplementation.

Always clarify the specific type of anemia with your physician before making significant dietary changes, as the wrong dietary approach can worsen certain forms.

What is anemia?

Anemia is a condition in which the circulating quantity of red blood cells (or the hemoglobin they contain) is insufficient to meet the body’s oxygen transport needs. It is detectable through a blood test measuring hemoglobin levels. Although iron deficiency is the most common cause, anemia has many possible origins, and treating it without identifying the cause is inadequate.

What is Mediterranean anemia?

Mediterranean anemia (beta-thalassemia) is an inherited blood disorder in which the body produces insufficient hemoglobin and destroys red blood cells at an abnormally rapid rate. The consequence is reduced tissue oxygenation. It can manifest in several forms with markedly different severity and clinical course.

What is pernicious anemia?

Pernicious anemia is an autoimmune condition that causes vitamin B12 deficiency. This happens because the immune system destroys gastric parietal cells, which produce intrinsic factor, the protein required to absorb B12 from the gut. Without intrinsic factor, B12 cannot be absorbed, and the resulting deficiency causes megaloblastic anemia and potentially irreversible neurological damage.

What is iron deficiency anemia (sideropaenic anemia)?

It is the most common form of anemia worldwide, caused by insufficient iron. This deficiency can result from inadequate dietary intake, impaired intestinal absorption (for example, celiac disease), or excessive iron loss (such as chronic bleeding from menorrhagia or gastrointestinal lesions).

What is sickle cell anemia?

A genetic disease in which the body produces structurally abnormal hemoglobin (hemoglobin S), causing red blood cells to assume a rigid, sickle shape. These abnormal cells cannot flow smoothly through small blood vessels, causing recurrent painful episodes (vaso-occlusive crises), chronic hemolytic anemia, and multi-organ complications.

What is hemolytic anemia?

Hemolytic anemia refers to a group of conditions characterized by premature, excessive destruction of circulating red blood cells. When the rate of destruction exceeds the bone marrow’s compensatory production capacity, anemia results. Causes include genetic red blood cell defects (G6PD deficiency, hereditary spherocytosis), autoimmune conditions, certain drugs, infections, and mechanical destruction.

What is aplastic anemia?

Aplastic anemia is a rare and potentially life-threatening form of bone marrow failure in which the bone marrow stops producing sufficient red blood cells, white blood cells, and platelets. It can be acquired (often autoimmune in origin) or inherited (as in Fanconi anemia).

What is megaloblastic anemia?

Megaloblastic anemia refers to a group of conditions characterized by the presence of abnormally large red blood cells (macrocytosis), caused by impaired DNA synthesis in developing red blood cell precursors. The most common causes are vitamin B12 and/or folate deficiency. Rarer causes include congenital metabolic disorders and certain medication effects.

How is anemia treated?

Treatment is entirely dependent on the underlying cause; there is no universal treatment. In some forms, the approach is opposite: for example, iron supplementation is the treatment for iron deficiency anemia but is contraindicated in thalassemia or sideroblastic anemia with iron overload. Always have the specific type of anemia clearly established by your physician before beginning any treatment.

What are the consequences of anemia?

Different forms have different consequences, but common manifestations shared across types include persistent fatigue (often the first and most prominent symptom), exertional breathlessness, pallor, and pica in some cases. The presence and severity of symptoms are not always proportional to the degree of blood count abnormality, as individual physiological reserve and the speed of anemia development influence symptom expression greatly.

When should anemia in pregnancy be a cause for concern?

Anemia is relatively common during pregnancy. The hemoglobin level used to define anemia varies depending on the stage of pregnancy, and different guidelines may use slightly different thresholds. As a general reference, hemoglobin levels of ≥11 g/dL in the first trimester and ≥10.5 g/dL around 28–30 weeks of pregnancy are considered within the normal range. Very low hemoglobin levels, particularly below 8.5 g/dL, are associated with an increased risk of adverse outcomes for the newborn. Hemoglobin levels below the expected range should be evaluated promptly by a physician or obstetrician to determine the cause and appropriate treatment.

---

Sources and Bibliography

• World Health Organization (WHO). “Worldwide prevalence of anaemia 1993–2005”. Geneva: WHO, 2008. https://www.who.int/vmnis/publications/anaemia_prevalence/en/
• Camaschella, C. (2015). “Iron-deficiency anemia”. New England Journal of Medicine, 372(19), 1832–1843. https://doi.org/10.1056/NEJMra1401038
• Auerbach, M., & Adamson, J. W. (2016). “How we diagnose and treat iron deficiency anemia”. American Journal of Hematology, 91(1), 31–38. https://doi.org/10.1002/ajh.24201
• Weiss, G., Ganz, T., & Goodnough, L. T. (2019). “Anemia of inflammation”. Blood, 133(1), 40–50. https://doi.org/10.1182/blood-2018-06-856500
• Stabler, S. P. (2013). “Vitamin B12 Deficiency”. New England Journal of Medicine, 368(2), 149–160. https://doi.org/10.1056/NEJMcp1113996
• Centers for Disease Control and Prevention (CDC). “Recommendations to Prevent and Control Iron Deficiency in the United States”. MMWR, 47(RR-3), 1998. https://www.cdc.gov/mmwr/preview/mmwrhtml/00051880.htm
• Pavord, S., et al. (2020). “UK guidelines on the management of iron deficiency in pregnancy”. British Journal of Haematology, 188(6), 819–830. https://doi.org/10.1111/bjh.16221
• Munoz, M., et al. (2017). “International consensus statement on the peri-operative management of anaemia and iron deficiency”. Anaesthesia, 72(2), 233–247. https://doi.org/10.1111/anae.13773
• Ganz, T. (2019). “Anemia of Inflammation”. New England Journal of Medicine, 381(12), 1148–1157. https://doi.org/10.1056/NEJMra1903038
• Goddard, A. F., et al. (2011). “Guidelines for the management of iron deficiency anaemia”. Gut, 60(10), 1309–1316. https://doi.org/10.1136/gut.2010.228874
• National Heart, Lung, and Blood Institute (NHLBI). “Anemia”. https://www.nhlbi.nih.gov/health/anemia
• MedlinePlus. “Anemia”. U.S. National Library of Medicine. https://medlineplus.gov/anemia.html
• Italian Ministry of Health. “Linee Guida per una Gravidanza Fisiologica”. https://www.salute.gov.it/
• Hershko, C., & Camaschella, C. (2014). “How I treat unexplained refractory iron deficiency anemia”. Blood, 123(3), 326–333. https://doi.org/10.1182/blood-2013-10-512624
• Lopez, A., et al. (2016). “Iron deficiency anaemia”. The Lancet, 387(10021), 907–916. https://doi.org/10.1016/S0140-6736(15)60865-0